8-K: Actelis Networks Prices $5M Public Offering

Actelis Networks, Inc. announced the pricing of a public offering to raise approximately $5 million in gross proceeds through the sale of common stock and warrants.

Summary

• Actelis Networks, Inc. offered and sold 4,352,500 shares of common stock, 1,897,500 pre-funded warrants, and 6,250,000 common warrants in a public offering.
• The purchase price was $0.80 per share and accompanying common warrant, and $0.7999 per pre-funded warrant and accompanying common warrant.
• Aggregate gross proceeds from the offering are expected to be approximately $5 million.
• Net proceeds to the company are approximately $4.46 million after deducting placement agent fees and estimated offering expenses.
• The pre-funded warrants are immediately exercisable at $0.0001 per share and do not expire until exercised in full.
• Each common warrant has an exercise price of $0.80 per share, is immediately exercisable, and will expire on the five-year anniversary of the issuance date.
• H.C. Wainwright & Co., LLC acted as the sole placement agent, receiving a 7.0% cash fee and a 1.0% management fee of the gross proceeds.
• The company also agreed to reimburse the placement agent $25,000 for non-accountable expenses and up to $100,000 for legal and other out-of-pocket expenses.
• The company will issue 437,500 warrants to the placement agent, representing 7.0% of the sum of shares and pre-funded warrants sold, with an exercise price of $1.00 per share and a five-year term.
• Proceeds from the offering are intended to advance pre-clinical and clinical studies and for general corporate purposes.
• The offering is expected to close on or about December 19, 2025, subject to customary closing conditions.

Sentiment

Score: 4

Explanation: While the capital raise provides necessary funding for Actelis Networks' operations and strategic initiatives, the significant dilution for existing shareholders and substantial fees paid to the placement agent indicate a less favorable outcome for current investors. The offering price at a discount also suggests a challenging fundraising environment.

Positives

• Secured approximately $4.46 million in net proceeds, providing capital for operations and strategic initiatives.
• The capital infusion is intended to advance pre-clinical and clinical studies, which could drive future growth.

Negatives

• Significant dilution for existing shareholders due to the issuance of new shares and warrants.
• Substantial fees and expenses paid to the placement agent, including a 7.0% cash fee, a 1.0% management fee, expense reimbursements, and additional warrants.
• The offering price of $0.80 per share suggests a discount, potentially indicating a challenging fundraising environment or a need to attract investors.

Risks

• The closing of the offering is subject to various customary conditions and contingencies, which, if not satisfied, could prevent the offering from closing.
• Forward-looking statements regarding the use of proceeds and future plans are not guaranteed and may not occur due to reasons beyond the company's control.
• Market and other conditions and assumptions could cause actual results to differ materially from historical experience and present expectations or projections.
• The trading price for common stock may fluctuate significantly.
• The company is subject to general risks described in its SEC filings.
• Potential for further dilution from the future exercise of the issued common warrants and placement agent warrants.
• The company has agreed to certain standstill restrictions for 30 days and a one-year prohibition on variable rate transactions (with limited exceptions).

Future Outlook

The company intends to use the net proceeds from the offering to advance its pre-clinical and clinical studies and for general corporate purposes. The offering is expected to close on or about December 19, 2025, subject to the satisfaction of customary closing conditions.

Management Comments

• The company intends to use the net proceeds from this offering for general corporate purposes.

Industry Context

Actelis Networks operates as a market leader in hybrid fiber, cyber-hardened networking solutions for wide-area IoT applications, serving sectors such as government, ITS, military, utility, rail, telecom, and campus networks. This capital raise is crucial for supporting its ongoing development, particularly its 'Cyber Aware Networking initiative' and AI-based cyber monitoring, enabling the company to maintain and expand its competitive position in these specialized and high-growth markets.

Stakeholder Impact

• Shareholders: Experience significant dilution due to the issuance of new common stock and warrants. Potential for further dilution upon the exercise of warrants.
• Company: Benefits from strengthened financial position with approximately $4.46 million in net proceeds, enabling funding for strategic initiatives and operational continuity.
• Placement Agent (H.C. Wainwright & Co., LLC): Receives substantial financial compensation through cash fees, management fees, expense reimbursements, and warrants for its role in facilitating the offering.

Next Steps

• The offering is expected to close on or about December 19, 2025, subject to customary closing conditions.
• The company plans to use the net proceeds to advance its pre-clinical and clinical studies.
• The company will use the net proceeds for general corporate purposes.
• The company will apply to list or quote all of the Shares and Warrant Shares on its Trading Market.

Key Dates

Recommendation

The capital raise provides essential funding for Actelis Networks' operations and strategic initiatives, which is a positive for the company's continuity. However, the significant dilution from the offering, coupled with the substantial fees paid to the placement agent, offsets much of this benefit for existing shareholders. The offering price at a discount also suggests a challenging fundraising environment. Given these mixed signals, a 'Hold' recommendation is appropriate, advising investors to monitor the company's execution of its strategic plans with the new capital and its ability to mitigate future dilution.

Keywords

Actelis Networks, ASNS, Public Offering, Common Stock, Warrants, Pre-Funded Warrants, Capital Raise, Equity Financing, Nasdaq Capital Market, H.C. Wainwright & Co., SEC Filing, Form 8-K, Dilution, IoT, Broadband, Cyber-hardened Networking